|
|
New Approaches to LDL Reduction
|
|
|
|
MTPIs – Efficacy comes from its dual mechanism of action
|
|
|
|
AEGR 733 HoFH Phase II Study Design
|
|
|
|
Change in Lipids Using Lomitapide with no Background Therapy
|
|
|
|
AEGR 733 HoFH Phase 3 Study Design (Ongoing)
|
|
|
|
HoFH Phase 3: 6-Month Lipid Efficacy
|
|
|
|
AEGR-733 Low Dose Development Program
|
|
|
|
Ezetimibe Combination Study: Mean LDL-C Efficacy
|
|
|
|
Impact of Low Dose MTPi on Hepatic Fat Levels (Mean Values at Week 12)
|
|
|
|
Summary of Adverse Event Experience with AEGR-733
|
|
Share this page with your colleagues and friends: